Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Prednisone
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
Prednisone is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Deltasone Tablets, 2.5 mg and 5 mg, of Pharmacia and Upjohn Co.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Zydus Cadila has received tentative approval from US Food and Drug Administration (FDA) to market tofacitinib extended-release tablets, 11 mg.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fosaprepitant
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic equivalent of Emend® for Injection, 150 mg Single-Dose Vial, of Merck indicated for adults in combination with other antiemetic agents.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vancomycin Hydrochloride
Therapeutic Area: Gastroenterology Product Name: Vancocin
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: ANI Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 25, 2020
Details:
Edge Pharma has signed an agreement with ANI Pharmaceuticals to market the company's FDA approved Vancomycin Hydrochloride for Oral Solution USP, a generic equivalent to Vancocin®.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
